Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 17
4 116
3 131
2 41
1 23
NEB 4
Curative setting
A 46
C 3
NEB 1
ESMO-MCBS Scores by tumour type
Non-curative setting
Breast Cancer 38
Central Nervous System Malignancies 0
Endocrine Tumours 20
Gastrointestinal Cancers 62
Genitourinary Cancers 60
Gynaecological Malignancies 34
Head and neck cancer 12
Refractory NTRK fusion-positive cancers 2
Sarcoma 9
Skin Cancers 27
TMB-H solid tumours 1
Thoracic Malignancies 66
dMMR/MSI-H solid tumour 1
Curative setting
Breast Cancer 8
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 1
Refractory NTRK fusion-positive cancers 0
Sarcoma 2
Skin Cancers 12
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumour 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Enzalutamide ADT (androgen deprivation therapy) ADT + placebo Treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) PROSPER
    Genitourinary Cancers
    		 Prostate cancer - PROSPER

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Docetaxel ADT (androgen deprivation therapy) ADT In combination with androgen-deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer CHAARTED
    Genitourinary Cancers
    		 Prostate cancer - CHAARTED

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Docetaxel ADT (androgen deprivation therapy) ADT In combination with androgen-deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer. CHAARTED
    Genitourinary Cancers
    		 Prostate cancer - CHAARTED

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Docetaxel ADT (androgen deprivation therapy) ADT In combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer STAMPEDE
    Genitourinary Cancers
    		 Prostate cancer - STAMPEDE

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Darolutamide ADT (androgen deprivation therapy) ADT + placebo Non-metastatic castration resistant prostate cancer for adult men who are at high risk of developing metastatic disease ARAMIS
    Genitourinary Cancers
    		 Prostate cancer - ARAMIS

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Apalutamide ADT (androgen deprivation therapy) ADT + placebo In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). TITAN
    Genitourinary Cancers
    		 Prostate cancer - TITAN

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pasireotide - Single arm Advanced carcinoids of the lung and thymus LUNA
    Endocrine Tumours
    		 Neuroendocrine Tumour - Lung and thymic carcinoids - LUNA

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Everolimus - Single arm Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease LUNA
    Endocrine Tumours
    		 Neuroendocrine Tumour - Lung and thymic carcinoids - LUNA

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Everolimus Pasireotide Single arm Advanced carcinoids of the lung and thymus LUNA
    Endocrine Tumours
    		 Neuroendocrine Tumour - Lung and thymic carcinoids - LUNA

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F3
      2
    Cetuximab Cisplatin or carboplatin plus 5-FU Cisplatin or carboplatin plus 5-FU First-line treatment of patients with recurrent or metastatic SCCHN EXTREME
    Head and neck cancer
    		 Squamous cell - EXTREME

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Nivolumab - Investigator choice (methotrexate or cetuximab or docetaxel) As monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy CheckMate141
    Head and neck cancer
    		 Squamous cell - CheckMate141

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      5
    Rucaparib - Single arm (Phase II) Platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. ARIEL2
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer BRCA mutation ARIEL2

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Rucaparib - Placebo Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy ARIEL3
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer Homologous recombination deficiencies (HRD) (BRCA mutant or BRCA wild-type and high loss of heterozygosity) ARIEL3

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Rucaparib - Placebo Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy ARIEL3
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer Germline or somatic - BRCA mutation ARIEL3

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Rucaparib - Placebo Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy ARIEL3
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer - ARIEL3

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Atezolizumab Carboplatin and etoposide Placebo plus carboplatin and etoposide First-line treatment of extensive-stage SCLC IMpower133
    Thoracic Malignancies
    		 Small-cell Lung Cancer - IMpower133

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Pembrolizumab - Cisplatin or carboplatin/5-FU/cetuximab As monotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 KEYNOTE-048
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥1 KEYNOTE-048

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pembrolizumab - Cisplatin or carboplatin/5-FU/cetuximab As monotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 KEYNOTE-048
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥20 KEYNOTE-048

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pembrolizumab Cisplatin or carboplatin/5-FU Cisplatin or carboplatin/5-FU/cetuximab In combination with platinum and 5‑fluorouracil (5‑FU) chemotherapy is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 KEYNOTE-048
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥1 KEYNOTE-048

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      4
    Pembrolizumab - Standard of care (methotrexate, docetaxel or cetuximab) Recurrent or metastatic SCCHN in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing ChT KEYNOTE-040
    Head and neck cancer
    		 Squamous cell CPS PD-L1 expression ≥1 KEYNOTE-040

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Sunitinib - Placebo Advanced GIST 2nd line after imatinib
    Sarcoma
    		 GIST - -

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Regorafenib Best supportive care Placebo plus best supportive care 3rd line after imatinib and sunitinib - patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib GRID
    Sarcoma
    		 GIST - GRID

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Pazopanib - Placebo Previously treated non-GIST metastatic soft tissue sarcoma PALETTE
    Sarcoma
    		 Soft tissue - PALETTE

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      3
    Eribulin - Dacarbazine Unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease
    Sarcoma
    		 Soft tissue - Liposarcoma or leiomyosarcoma - -

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    FINAL SCORE

    • F2a
      3
    Imatinib 1-year - Placebo Adjuvant for GIST patients had complete gross resection of a primary gastrointestinal stromal tumour at least 3 cm in size and positive for the KIT protein by immunohistochemistry ACOSOG Z9001
    Sarcoma
    		 GIST KIT+ ACOSOG Z9001

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Imatinib 3-years - Imatinib 1-year Adjuvant for high-risk GIST patients with KIT-positive GIST removed at surgery SSG XVIII
    Sarcoma
    		 GIST KIT+ SSG XVIII

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    FINAL SCORE

    • F1

      A
    Olaparib - Placebo Maintenance treatment of adult patients with gBRCAm who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line ChT regimen POLO
    Gastrointestinal Cancers
    		 Pancreatic cancer gBRCAm POLO

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    FINAL SCORE

    • F2b
      2
    Entrectinib - Single arm trials (Phase I/II) Adult and paediatric patients 12 years of age and older with solid tumours expressing an NTRK gene fusion, who have disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options STARTRK-1; STARTRK-2; ALKA-372-001
    Refractory NTRK fusion-positive cancers
    		 - NTRK gene fusion STARTRK-1; STARTRK-2; ALKA-372-001

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Entrectinib - Single arm Treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors STARTRK-1; STARTRK-2; ALKA-372-001
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer Refractory NTRK fusion–positive cancers STARTRK-1; STARTRK-2; ALKA-372-001

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3
    Avapritinib - Single arm Treatment of adult patients with unresectable or metastatic GIST harbouring the platelet-derived growth factor receptor alpha D842V mutation NAVIGATOR
    Sarcoma
    		 GIST PDGFRA D842V-mutant NAVIGATOR

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    FINAL SCORE

    • F3
      3

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.